NB4, HL60, K562, Jurkat, and U937 cell lines were maintained in RPMI 1640 medium supplemented with 10% of fetal bovine serum (FBS, Gibco, Paisley, UK), 1% of L-glutamine (Lonza, Verviers, Belgium) and 1% of penicillin/streptomycin (Euroclone, Pero, MI, Italy) in a humidified atmosphere at 37 °C and 5% of CO2. Cell lines were originally obtained from ATCC repository and routinely tested by PCR method and MycoAlert (Lonza, Verviers, Belgium #LT07-318) for mycoplasma contamination by the European Institute of Oncology (Milan, Italy).
Maltonis was synthesized as already described [20 (link)] and used for the treatments of cells (stock solution of 10 mM diluted in distilled water) at the reported concentrations for 24 h [19 (link)]. Western blot analyses were performed as previously reported [23 (link)] using the following antibodies: anti-H3K9me3 (#39766, Active Motif, Carlsbad, CA, USA, 1:1000 dilution), anti-α-tubulin (#T9026, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany, 1:500 dilution), anti-Histone H3 (#05-499, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany, 1:500 dilution), anti-c-MYC (Y69, Abcam, Cambridge, MA, USA, 1:1000 dilution), and images acquired using Vü-C Imaging system (PopBio, Cambridge, UK).
Maltonis was synthesized as already described [20 (link)] and used for the treatments of cells (stock solution of 10 mM diluted in distilled water) at the reported concentrations for 24 h [19 (link)]. Western blot analyses were performed as previously reported [23 (link)] using the following antibodies: anti-H3K9me3 (#39766, Active Motif, Carlsbad, CA, USA, 1:1000 dilution), anti-α-tubulin (#T9026, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany, 1:500 dilution), anti-Histone H3 (#05-499, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany, 1:500 dilution), anti-c-MYC (Y69, Abcam, Cambridge, MA, USA, 1:1000 dilution), and images acquired using Vü-C Imaging system (PopBio, Cambridge, UK).
Free full text: Click here
